missing translation for 'onlineSavingsMsg'
Learn More

Human IL-29 (IFN lambda 1) Carrier-Free, Invitrogen™

Recombinant Protein

Brand:  Invitrogen 34-8298-64

Product Code. 15538776

This item is not returnable. View return policy

Description

Description

IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low levels of costimulatory molecules. Moreover, these cells can specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cells with contact-dependent suppressive activity. Description: IFN-lambdas constitute a novel family of interferons that mediate the induction of anti-viral protection in a wide variety of cells. There are three members in this family, namely lambda1, lambda2, and lambda3, which are also known as IL-29, IL-28A, and IL-28B, respectively. Similar to type I IFNs, IFN-lambdas activate an intracellular signaling to promote gene expression. IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex composed of two essential receptor proteins, CRF2-12/IFN-lambdaR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. The IFN-lambdas, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. DCs that differentiate in response to IFN-lambdas express high levels of class I and II MHC gene products, but low levels of costimulatory molecules. Moreover, these cells can specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cells with contact-dependent suppressive activity. Applications Reported: This protein has been demonstrated to induce STAT2 phosphorylation. Applications Tested: Recombinant human IL-29 (IFN lambda 1) is biologically active and can induce STAT2 phosphorylation. Source: E. coli (amino acids Pro23-Thr178; accession # NP_742152.1). Bioactivity: This protein has been demonstrated to induce STAT2 phosphorylation. Endotoxin: Less than 0.1ng/ug cytokine as determined by the LAL assay. Purity: >98% as determined by SDS-PAGE and HPLC. Molecular Weight: 19.8 kDa. Storage and handling: For best recovery, quick spin vial prior to opening. Use in sterile environment. Reconstitute in water to a concentration of less than 0.5 - 1.0mg/mL. Do not vortex. Store lyophilized protein at less than or equal to -20°C. Reconstituted protein solution can be stored with carrier protein (e.g., 0.1% BSA) at less than or equal to -20°C.
TRUSTED_SUSTAINABILITY
Specifications
Show More
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title
Human IL-29 (IFN lambda 1) Carrier-Free, Invitrogen™ > 20μg; Unlabeled

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.